Use of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Nodal Staging in Prostate Cancer and Tailoring of Treatment: A Continuing Conundrum.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39701872.
- Also identified by DOI 10.1016/j.eururo.2024.11.025.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Trials have shown that prostate-specific membrane antigen (PSMA)-based positron emission tomography/computed tomography (PET/CT) is more accurate than conventional imaging for staging of nodal status in prostate cancer. We discuss the advantages of PSMA PET/CT over current options for nodal staging and highlight the issues that need to be resolved for implementation of this modality in routine practice.
Medical subject headings
- Antigens, Surface
- Glutamate Carboxypeptidase II
- Lymph Nodes
- Positron Emission Tomography Computed Tomography
- Prostatic Neoplasms